NEUROMEKA CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30,850 KRW | -3.29% |
|
+0.16% | -16.96% |
| 2023 | Neuromeka Co.,Ltd.(KOSDAQ:A348340) added to S&P Global BMI Index | CI |
| 2023 | Neuromeka Participates in FABTECH 2023, Unveiling 3D Vision Collaborative Robot Welding Solution | CI |
Valuation
| Fiscal Period: December | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 128,677 | 324,902 | - | - |
| Enterprise Value (EV) 1 | 128,677 | 324,902 | 324,902 | 324,902 |
| P/E ratio | - | - | - | - |
| Yield | - | - | - | - |
| Capitalization / Revenue | 13.2 x | 12.9 x | 9.56 x | 7.06 x |
| EV / Revenue | 13.2 x | 12.9 x | 9.56 x | 7.06 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | 9.78 x | 8.67 x | 7.17 x |
| Nbr of stocks (in thousands) | 10,336 | 10,532 | - | - |
| Reference price 2 | 12,450 | 30,850 | 30,850 | 30,850 |
| Announcement Date | 3/15/23 | - | - | - |
1KRW in Million2KRW
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 9.755 | 25.17 | 34 | 46 |
| EBITDA | - | - | - | - | - |
| EBIT 1 | - | -7.798 | 1.133 | 5 | 10 |
| Operating Margin | - | -79.94% | 4.5% | 14.71% | 21.74% |
| Earnings before Tax (EBT) | - | - | - | - | - |
| Net income | -6.594 | -8.201 | - | - | - |
| Net margin | - | -84.07% | - | - | - |
| EPS | -4,581 | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| FCF margin | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/31/22 | 3/15/23 | - | - | - |
1KRW in Billions
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 |
|---|---|
| Net sales 1 | 0.968 |
| EBITDA | - |
| EBIT 1 | -2.529 |
| Operating Margin | -261.25% |
| Earnings before Tax (EBT) | - |
| Net income 1 | -2.185 |
| Net margin | -225.72% |
| EPS 2 | -211.0 |
| Dividend per Share | - |
| Announcement Date | 5/26/23 |
1KRW in Billions2KRW
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | 1.3% | 12.1% | 19% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets | - | - | - | - | - |
| Book Value Per Share 1 | - | - | 3,154 | 3,557 | 4,303 |
| Cash Flow per Share 1 | - | - | 454.0 | 1,082 | 1,491 |
| Capex 2 | - | - | 8 | 8 | 8 |
| Capex / Sales | - | - | 31.79% | 23.53% | 17.39% |
| Announcement Date | 3/31/22 | 3/15/23 | - | - | - |
1KRW2KRW in Billions
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
30,850
KRW
Average target price
53,000
KRW
Spread / Average Target
+71.80%
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.96% | 235M | |
| +15.59% | 88.04B | |
| +23.44% | 73.1B | |
| +29.74% | 40.48B | |
| +23.52% | 34.25B | |
| +7.18% | 27.78B | |
| +9.98% | 27.2B | |
| -0.55% | 25.62B | |
| +24.50% | 26.32B | |
| +5.43% | 22.4B |
- Stock Market
- Equities
- A348340 Stock
- Financials Neuromeka Co., Ltd.
